Insider account of UCB’s $2.1B deal to buy Ra Pharma spotlights a disciplined M&A strategy and $120M windfall for execs – Endpoints News

Posted: December 2, 2019 at 5:46 am

At an old Amgen facility tucked just beyond the Rockies. In a warehouse behind a Walmart supercenter in Durham, North Carolina. On a long-time Bristol Myers Squibb site outside Princeton. The tech has emerged, and now the arms race to physically build a generation of gene therapies has begun.

Novartis will spend $500 million scaling its gene therapy manufacturing efforts, Reuters reported today. Thatll put it nearly on par with Pfizer, who committed $600 million for its facilities even before any of its gene therapies have been approved. Together, 11 companies Reuters surveyed will spend $2 billion on gene therapy production.

Additionally, the Boston Globereported today that Vertex had completed its search for a gene therapy research and manufacturing campus in Boston, settling on a 256,000 square-foot center at the Raymond Flynn Marine Industrial Park.

Unlock this story instantly and join 66,600+ biopharma pros reading Endpoints daily and it's free.

SUBSCRIBE SIGN IN

Continue reading here:
Insider account of UCB's $2.1B deal to buy Ra Pharma spotlights a disciplined M&A strategy and $120M windfall for execs - Endpoints News

Related Post

Comments are closed.

Archives